欧盟批准膀胱癌治疗后，ImmunityBio上升

2026-02-18 23:06

ImmunityBio (IBRX) traded higher on Wednesday after the European Commission issued a conditional marketing authorization for its bladder cancer therapy, Anktiva, expanding its use in more than two dozen EU countries.
The decision came after an expert panel of the EU drug regulator, the European Medicines Agency, endorsed the immunotherapy in December as part of a combination regimen for a type of invasive bladder cancer.
Specifically, the authorization allows the company to market Anktiva across 27 countries in combination with Bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non-muscle invasive bladder cancer.
As part of the condition approval, which was based on IBRX’s Phase 2/3 QUILT-3.032 study, ImmunityBio (IBRX) is required to provide EU regulators with long-term safety and efficacy data related to Anktiva.

More on ImmunityBio